A study evaluating the effect of bhumyamalaki curna with tandulodaka for 3 days in abnormal uterine bleeding

A single arm pilot study study evaluating the effect of bhumyamalaki curna with tandulodaka for 3 days in abnormal uterine bleeding assessed by PBAC score - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/02/103762

Enrollment

Registered

2026-02-12

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N939- Abnormal uterine and vaginal bleeding, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. History of HMB for past 3 cycles, 2. PBAC score equal or greater than 100 for previous menstrual cycle

Exclusion criteria

Exclusion criteria: 1. Diagnosed cases of AUB with structural causes, any other pelvic structural pathologies identified by USG 2. Hb value less than 10 g per dL 3. Participants who have inserted Intrauterine device 4. Participants who are UPT Positive 5. Known case of DM, HTN, Thyroid dysfunction and or any other bleeding disorder and or who are under any other medications.

Design outcomes

Primary

Measure	Time frame
Change in quantity of menstrual bleeding using PBAC score Pre-intervention assessment- PBAC score of the entire menstrual cycle immediately preceding drug administration (as documented in the inclusion criteria: PBAC greater than or equal to 100) will be documemted. Post-intervention assessment- PBAC score calculated from the entire menstrual cycle during which the trial drug will be administered for first three daysTimepoint: 1. Day 0 2. After completion of menstrual cycle	—

Measure

Time frame

Change in quantity of menstrual bleeding using PBAC score Pre-intervention assessment- PBAC score of the entire menstrual cycle immediately preceding drug administration (as documented in the inclusion criteria: PBAC greater than or equal to 100) will be documemted. Post-intervention assessment- PBAC score calculated from the entire menstrual cycle during which the trial drug will be administered for first three daysTimepoint: 1. Day 0 2. After completion of menstrual cycle

—

Secondary

Measure	Time frame
1. Duration of bleeding 2. HbTimepoint: 1. Day 0 2. After completion of menstrual cycle	—

Countries

India

Contacts

Public ContactDr Anjaly M V

AMRITA SCHOOL OF AYURVEDA

dr.anjali@ay.amrita.edu9495114149

Outcome results